Dermatology Times

Stefan Weiss, MD, MHSc, MBA

Kaitlyn Bader, Senior Editor

OM1 is a large-scale data analytics company with a dedication to improving health outcomes through targeted research. Dermatology Times® recently spoke with Stefan Weiss, MD, MHSc, MBA, a board-certified dermatologist and the managing director of dermatology at OM1, to discuss the company’s role in analyzing dermatologic conditions and efficacious treatments. Through data analysis, collection, and research, OM1 is able to create data-ready sets for psoriasis, hidradenitis suppurativa, atopic dermatitis, vitiligo, and alopecia areata.

“At the end of the day, what we want to do is bring the right drug to the right person at the right time. We all are in dermatology for the purpose of making the lives of our patients better. Historically, we’ve relied on case reports and case series in one-offs. But to take datasets of 75 to 150,000 individuals in a well-represented geographic, gender, ethnic, and racial cohort and see how treatment paradigms are similar, how they’re different, and where we can tweak those treatment paradigms such that we can maximize the clinical benefit of patients is a tremendous asset, and having the opportunity to partner with the AAD to do that really brings a great advantage to the specialty and to our patients.” said Weiss.